Rankings
▼
Calendar
KNSA Q2 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
Gross Profit
$4M
54.8% margin
Operating Income
-$41M
-526.4% margin
Net Income
-$42M
-539.5% margin
EPS (Diluted)
$-0.61
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$39M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$279M
Total Liabilities
$43M
Stockholders' Equity
$236M
Cash & Equivalents
$168M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$0
—
Gross Profit
$4M
$0
—
Operating Income
-$41M
-$32M
-27.3%
Net Income
-$42M
-$37M
-10.9%
← FY 2021
All Quarters
Q3 2021 →